Voya Investment Management LLC Acquires 133,703 Shares of Progyny, Inc. $PGNY

Voya Investment Management LLC grew its holdings in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 258.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 185,495 shares of the company's stock after purchasing an additional 133,703 shares during the period. Voya Investment Management LLC owned about 0.22% of Progyny worth $4,144,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of PGNY. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Progyny in the first quarter worth $44,000. Militia Capital Partners LP bought a new stake in shares of Progyny in the first quarter worth $45,000. Brooklyn Investment Group grew its holdings in shares of Progyny by 5,216.4% in the first quarter. Brooklyn Investment Group now owns 3,243 shares of the company's stock worth $72,000 after acquiring an additional 3,182 shares during the period. GAMMA Investing LLC grew its holdings in shares of Progyny by 233.9% in the first quarter. GAMMA Investing LLC now owns 5,379 shares of the company's stock worth $120,000 after acquiring an additional 3,768 shares during the period. Finally, AlphaQuest LLC grew its holdings in shares of Progyny by 57.9% in the first quarter. AlphaQuest LLC now owns 5,668 shares of the company's stock worth $127,000 after acquiring an additional 2,079 shares during the period. Institutional investors own 94.93% of the company's stock.

Progyny Stock Performance

Shares of PGNY opened at $21.62 on Friday. The business's 50-day moving average is $22.92 and its two-hundred day moving average is $22.20. The company has a market capitalization of $1.86 billion, a P/E ratio of 36.64, a P/E/G ratio of 1.84 and a beta of 1.33. Progyny, Inc. has a fifty-two week low of $13.39 and a fifty-two week high of $26.76.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.19 earnings per share for the quarter, missing the consensus estimate of $0.42 by ($0.23). Progyny had a return on equity of 10.69% and a net margin of 4.28%.The company had revenue of $332.87 million for the quarter, compared to analyst estimates of $315.70 million. During the same period in the prior year, the business posted $0.17 earnings per share. Progyny's revenue for the quarter was up 9.5% on a year-over-year basis. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. Analysts forecast that Progyny, Inc. will post 0.6 EPS for the current year.

Insider Transactions at Progyny

In other news, Director Kevin K. Gordon sold 2,500 shares of the firm's stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $22.04, for a total transaction of $55,100.00. Following the sale, the director directly owned 12,501 shares in the company, valued at $275,522.04. This trade represents a 16.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Allison Swartz sold 2,398 shares of the firm's stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $22.96, for a total value of $55,058.08. Following the sale, the executive vice president owned 79,697 shares in the company, valued at $1,829,843.12. This trade represents a 2.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 7,895 shares of company stock worth $179,311 over the last 90 days. Insiders own 9.40% of the company's stock.

Analyst Upgrades and Downgrades

PGNY has been the topic of several analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and set a $28.00 target price (up from $26.00) on shares of Progyny in a research report on Friday, August 8th. Canaccord Genuity Group lifted their target price on Progyny from $21.00 to $23.00 and gave the company a "hold" rating in a research report on Wednesday, August 20th. Wall Street Zen upgraded Progyny from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Leerink Partners upgraded Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 price objective on the stock in a research report on Tuesday, July 8th. Finally, Truist Financial boosted their price objective on Progyny from $24.00 to $27.00 and gave the company a "hold" rating in a research report on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $25.44.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.